InnoCare Pharma Begins Phase III Trial of Orelabrutinib for Systemic Lupus Erythematosus Treatment

Key Takeaways

• InnoCare Pharma has dosed the first patient in a Phase III trial of orelabrutinib for systemic lupus erythematosus (SLE)
• The randomized, double-blind, placebo-controlled study represents a potential new treatment option for SLE patients
• This milestone advances orelabrutinib toward potential regulatory approval as a BTK inhibitor therapy for autoimmune diseases

---

BEIJING - InnoCare Pharma (HKEX: 9969; SSE: 688428) announced April 28, 2026, that the first patient has been dosed in its registrational Phase III clinical trial evaluating orelabrutinib for systemic lupus erythematosus (SLE) treatment.

The biopharmaceutical company, which focuses on cancer and autoimmune disease treatments, is conducting a randomized, double-blind, placebo-controlled, multicenter Phase III study to assess the efficacy and safety of its novel BTK inhibitor in SLE patients.

Significance for SLE Treatment

Systemic lupus erythematosus affects millions worldwide, causing the immune system to attack healthy tissues and organs. Current treatment options remain limited, creating significant unmet medical need for effective therapies.

Orelabrutinib works by inhibiting Bruton’s tyrosine kinase (BTK), a protein crucial in B-cell signaling pathways involved in autoimmune responses. BTK inhibitors have shown promise in treating various autoimmune conditions by reducing abnormal immune system activity.

Clinical Development Progress

This Phase III trial represents a critical milestone in orelabrutinib’s development for autoimmune indications. The study design follows regulatory standards for drug approval, with the multicenter approach enabling broader patient enrollment and more robust data collection.

InnoCare has previously demonstrated orelabrutinib’s potential in oncology applications, and this expansion into autoimmune diseases reflects the company’s strategic diversification.

Market Impact

The SLE therapeutics market continues growing as pharmaceutical companies seek to address treatment gaps. Successful completion of this Phase III trial could position orelabrutinib as a competitive option in the autoimmune disease space.

Patient enrollment and study completion timelines will be critical factors determining when potential regulatory submissions might occur. The company has not disclosed specific enrollment targets or expected study duration.

---

Frequently Asked Questions

What does this mean for SLE patients?

This Phase III trial could lead to a new treatment option for SLE patients if the study demonstrates orelabrutinib’s safety and efficacy. However, the drug must complete the full clinical trial and receive regulatory approval before becoming available to patients.

When will orelabrutinib be available for SLE treatment?

The timeline depends on Phase III trial completion, data analysis, and regulatory review processes. Typically, Phase III trials take 2-4 years to complete, followed by 6-12 months for regulatory approval, though timelines can vary significantly.

How does orelabrutinib compare to existing SLE treatments?

Orelabrutinib represents a different mechanism of action as a BTK inhibitor compared to current SLE therapies. Its comparative effectiveness, safety profile, and patient outcomes versus existing treatments will be determined through the Phase III trial results.